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A BST R A C T 
 
Null mutations in GRN are associated with Frontotemporal Lobar  with TDP-43 inclusions (FTLD-
TDP). However the influence of progranulin (PGRN) deficiency in neurodegeneration is largely 
unknown. In neuroblastoma cells, silencing of GRN gene causes significantly reduced cell survival 
after serum withdrawal. The following observations suggest that alterations of the CDK4/6/pRb 
pathway, secondary to changes in PI3K/Akt and ERK1/2 activation induced by PGRN deficiency, 
are involved in the control of serum deprivation-induced apoptosis. (i) Inhibiting CDK4/6 levels or 
their associated kinase activity by sodium butyrate or PD332991 sensitized control SH-SY5Y cells 
to serum deprivation-induced apoptosis without affecting survival of PGRN deficient cells. (ii) 
CDK4/6/pRb seems to be downstream of the PI3K/Akt and ERK1/2 signaling pathways since their 
specific inhibitors, LY294002 and PD98059, were able to decrease CDK6-associated kinase 
activity and induced death of control SH-SY5Y cells. (iii) PGRN deficient cells show reduced 
stimulation of PI3K/Akt, ERK1/2 and CDK4/6 activities compared with control cells in the 
absence of serum. (iv) supplementation of recombinant human PGRN was able to rescue survival 
of PGRN deficient cells. These observations highlight the important role of PGRN-mediated 
stimulation of the PI3K/Akt-ERK1/2/CDK4/6/pRb pathway in determining the cell fate 
survival/death under serum deprivation.  
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IN T R O DU C T I O N 
The term Frontotemporal Lobar Degeneration (FTLD) refers to a group of progressive brain rare diseases, 
which involve shrinkage of specific areas of the brain that regulate behavior, personality and language. 
The onset of symptoms usually occurs before the age of 60 years, accounting for 5-10% of dementia 
patients [1,2]. 
The neuropathological hallmark of FTLD is the degeneration of frontal and temporal lobes, as well as the 
accumulation of protein inclusions in neuronal and glial cells [3]. FTLD subtypes have been established 
depending on the proteins found in these inclusions. The main subtypes are FTLD-tau and FTLD-TDP 
for microtubule associated protein tau (MAPT) and FTLD-TDP for ubiquitinated transactive response 
DNA-binding protein 43 (TDP-43) positive inclusions respectively [4-6]. A large subset of FTLD-TDP 
patients has been identified to harbor loss-of-function mutations (including null mutations) in the gene 
encoding progranulin (GRN) [7,8], and a smaller number of mutations in the valosin-containing protein 
(VCP) gene [9], transactive response (TAR) DNA-binding protein-43 (TARDBP) [10] sequestome1/p62 
(SQSTM1) [11] and ubiquilin-2 (UBQLN2) [12]. A C9ORF72 hexanucleotide expansion in chromosome 
9 has been described to be responsible for familial Frontotemporal Dementia overlapping with motor 
neuron disease (FTD-MND) cases and amyotrophic lateral sclerosis (ALS) [13,14]. GRN mutations are 
dominantly inherited and the disease mechanism is postulated to be haploinsufficiency, as most GRN 
mutations lead to an approximately 50% reduction in PGRN levels [15-17]. 
PGRN is a 593 amino acid, 86 kDa cysteine rich protein containing a signal peptide and 7.5 repeats of 
highly conserved granulin motifs [18]. PGRN is widely distributed [19], including the central nervous 
system (CNS) [20]. Previous research has suggested that PGRN may function as an autocrine neuronal 
growth factor involved in the inflammatory neuronal repair process in the CNS [21]. PGRN has been 
reported to promote neuronal survival in culture [22], though the degree of this effect is controversial 
[23]. The effects of PGRN deficit in the CNS have been also studied in GRN knockdown neuronal cells 
[24,25] and knockout mice (GRN-/-). The GRN silenced neuronal cells were shown to display some of the 
phenotypic characteristics of the disease such as increased cytosolic accumulation of TDP-43 and 
increased vulnerability of neurons to normally sublethal insults [25]. Increased caspase activation and 
decreased TDP-43 solubility was also found in GRN KD cortical neurons [26].  On the other hand, GRN-
/- mice develop ubiquitin-positive aggregates and phosphorylated TDP-43, similar to FTLD-TDP patients 
 4 
[27,28]. Thus, it seems that GRN KD neuronal cells is a suitable experimental model to study FTLD-TDP 
associated with loss-of-function GRN mutations. 
Previous work from this laboratory highlighted the role of the CDK6/pRb pathway in controlling cell fate 
survival/death of peripheral cells from carriers of a loss-of-function GRN mutation, c.709-1G>A [29]. In 
this work, we have addressed the issue as to whether PGRN deficiency also modulates this cascade, and 
eventually cell survival in a neuroblastoma cell line. For this purpose, we used a stable clone of SH-
SY5Y cells in which GRN expression was knocked down by a vector-based shRNA approach [24]. 
Compared with control cells, survival of GRN KD SH-SY5Y cells was severely reduced in serum-free 
medium. Our results suggest that alterations in the CDK4/6/pRb pathway, secondary to changes in the 
activity of the PI3K/Akt and ERK1/2 pathways induced by PGRN deficiency, are involved in the control 
of serum deprivation-induced apoptosis. 
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M A T E RI A LS A ND M E T H O DS 
Mater ials 
All components for cell culture were obtained from Invitrogen (Barcelona, Spain). LY294002 and 
PD98059 were obtained from Calbiochem (Darmstadt, Germany). Progranulin (human recombinant) was 
obtained from Enzo (Zandhoven, Belgium). Elastase from human leukocytes, Epidermal growth factor 
(EGF), the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide reactive (MTT), and the 
inhibitor of histone deacetylases, sodium butyrate (SB), were obtained from Sigma-Aldrich (Tres Cantos, 
Spain). The inhibitor of CDK6/CDK4-associated kinase activity, PD332991, was obtained from Pfizer 
(Gronton, Connecticut, US). 4,6-diamino-2-phenylindole (DAPI) and insulin were obtained from Life 
Technologies (Eugene, Oregon, US). Antibodies used in this study are listed in Table 1. Poly (vinylidene) 
fluoride (PVDF) membranes were purchased from Merk Millipore (Billerica, Massachusetts, US). The 
enhanced chemiluminiscence (ECL) system was from Amersham (Uppsala, Sweden). Other reagents 
were of molecular biology grade.  
GRN knockdown neuroblastoma SH-SY5Y cell lines 
Stable GRN knockdown neuroblastoma SH-SY5Y cells (Clone # 207) was a generous gift from Drs. 
Joselin and Wu from the Center for Genetic Medicine (Northwestern University, Chicago, Il US). GRN 
knockdown was achieved by using pSUPERIOR RNAi construct as previously described [24]. The target 
sequence of 19 nucleotides targeted against nucleotides 207–226 (#207) of the human GRN mRNA was 
designed. The 64 nt short hairpin RNA sense and antisense primer  sequences  were  5’-
gatccccggccactcctgcatctttattcaagagataaagatgcaggagtggcctttttggaaa-3’  and 
5’agcttttccaaaaaggccactcctgcatctttatctcttgaataaagatgcaggagtggccggg-3’. 
The sense and antisense primer pairs were annealed and ligated into the pSUPERIOR vector 
(OligoEngine)  according  to manufacturer’s  instructions.  The  vector  control was  also  stably  introduced 
into SH-SY5Y cells to generate the control cell line. 
M T T colorimetr ic survival assay 
Active mitochondria of living cells can cleave MTT to produce formazan, the amount of which is directly 
proportional to the living cell number. Cell survival was assessed essentially as described [30]. Cells 
(60,000) were incubated with 0.25 µg/µl of MTT in a reaction volume of 200 l. After the incubation, 
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DMSO was added to dissolve formazan crystals. Dye absorbance in viable cells was measured at 590 nm 
with 620 nm as a reference wavelength. Cell survival was estimated as the percentage of the value of 
untreated controls.  
Assessment of apoptosis and caspases activity 
Apoptosis was characterized by chromatin condensation/fragmentation, as determined by cell fixation 
followed by 4,6-diamidino-2-phenylindole (DAPI) staining and fluorescence microscopy examination. 
The activation of executive caspases was investigated using the Vybrant® FAM Caspase-3 and 7 Kit 
(Invitrogen, Carlsbad, CA, USA) including FLICA reagent that is retained within the cell, if bound to the 
active caspase molecule. Control and GRN KD SH-SY5Y were resuspended in 300 µl of RPMI 
containing 10 µl of FLICA reagent and incubated in 5% CO2 at 37ºC for 60 min. The cells were then 
washed and suspended in wash buffer provided by the kit. The samples were analyzed on the flow 
cytometer. 
Immunoblotting analysis 
Cells were harvested, washed in PBS and then lysed in ice-cold lysis buffer (50 mM Tris pH 7.4, 150 mM 
NaCl, 50 mM NaF, 1% Nonidet P-40), containing 1 mM sodium orthovanadate, 1 mM 
phenylmethylsulfonyl flouride (PMSF), 1 mM sodium pyrophosphate and protease inhibitor Complete 
Mini Mixture (Roche, Mannheim, Germany). 20 to 50 µg of protein from cell extracts were fractionated 
on a sodium dodecyl sulfate (SDS) polyacrylamide gel, and transferred to PVDF membrane. The 
membranes were then blocked with Bovine Serum Albumin (BSA) (Sigma) or dry milk and incubated 
with primary antibodies as is indicated in Table 1. The release of cytochrome c from the mitochondria 
was assessed after cell fractioning to get cytosolic and crude mitochondrial extracts as described [31], 
using the ApoTrack™ Cytochrome c Apoptosis Antibody Cocktail. Signals from the primary antibodies 
were amplified using species-specific antisera conjugated with horseradish peroxidase (Bio-Rad) and 
detected with a chemiluminiscent substrate detection system ECL (Amersham). The antibody specificity 
was checked by omitting the corresponding primary antibody in the incubation medium. Protein band 
densities were quantified using Image J software (National Institutes of Health, Bethesda, Maryland, 
USA) after scanning the images with a GS-800 densitometer from Bio-Rad and normalized by those of -
actin or α-tubulin. When indicated cytosolic or mitochondrial proteins were normalized by GAPDH and 
C-V-α or PDH-E1-α respectively. 
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Quantitative real-time PC R 
Total RNA was extracted from cell cultures using Trizol® reagent (Invitrogen, Alcobendas, Madrid, 
Spain). RNA yields were quantified spectrophotometrically and RNA quality was checked by the 
A260/A280 ratio and on a 1.2% agarose gel to determine the integrity of 18S and 28S ribosomal 
RNA. RNA was then treated with DNase I Amplification Grade (Invitrogen, Alcobendas, Madrid, Spain). 
One microgram was reverse transcribed with the Superscript III Reverse Transcriptase kit (Invitrogen, 
Alcobendas, Madrid, Spain). Quantitative real-time polymerase chain reaction (PCR) was performed in 
triplicates using TaqMan® Universal PCR MasterMix No Amperase UNG (Applied Biosystems, 
Alcobendas, Madrid,  Spain)  reagent  according  to  the  manufacturer’s  protocol.  Primers  were  designed 
using the Universal Probe Library for Human (Roche Applied Science, Madrid, Spain) and used at a final 
concentration of 20 μM. The sequences of  the  forward and  reverse primers used are  the  following:  for 
GRN,  5’-tctgtagtctgagcgctaccc-3’  and  5’-agggtccacatggtctgc-3’;  for  β-actin,  5’-ccaaccgcgagaagatga-3’ 
and 5’-ccagaggcgtacagggatag-3’. Real time quantitative PCR was performed in the Bio-Rad iQ5 system 
using a thermal profile of an initial 5-minute melting step at 95 ºC followed by 40 cycles at 95 ºC for 10 
seconds and 60 ºC for 60 seconds. Relative messenger RNA (mRNA) levels of the genes of interest were 
normalized to -actin expression using the simplified comparative threshold cycle delta-delta CT method 
(2-[ΔCT GRN -ΔCT Actin]). 
Statistical analysis 
Statistical analyses were performed on GraphPad Prism 5 for Macintosh (La Jolla, CA, USA). All the 
statistical data are presented as mean ± standard error of the mean (SEM). Statistical significance was 
estimated by analysis of variance (ANOVA) followed by the Bonferroni`s test for multiple comparisons. 
Differences were considered significant at a level of p<0.05. 
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R ESU L TS 
GRN knockdown increased the vulnerability of cells to serum deprivation 
To study the effects of PGRN deficiency on cell survival, we took advantage of stable GRN knockdown 
SH-SY5Y (GRN KD cells), generated in Dr. Wu lab with a pSUPERIOR RNAi construct containing the 
target sequence corresponding to nucleotide sequences 207 to 226 specific for human GRN gene [24]. As 
shown in Fig. 1 A, B, a considerable decrease in GRN mRNA and protein content were observed in KD 
cells compared with control SH-SY5Y cells expressing the empty vector. After serum deprivation, we 
found marked differences in cell survival between control and GRN KD cells as assessed by the MTT 
assay.  While in control cultures, a large number of cells still survive 4 days after serum deprivation, in 
PGRN deficient cells there was an important reduction in cell viability from the first day (Fig. 1C).  
Extracellular P G RN protects GRN K D cells from serum deprivation-induced cell death 
To explore whether PGRN is able to protect SH-SY5Y cells from serum withdrawal, we treated GRN KD 
cells with exogenous rhPGRN for 3 days. Fig. 2A shows that the addition of exogenous rhPGRN was 
able to increase the percentage of survival of PGRN deficient cells up to the levels found in control cells. 
The effect of rhPGRN disappeared when it was previously degraded by elastase (Fig. 2A). As shown in 
Fig. 2B, left panel, incubation of rhPGRN with 0.1 U/ml of elastase for three hours was sufficient to 
completely degrade PGRN.  In addition, the stability of extracellular rhPGRN in the cell culture was 
checked by collecting conditioned medium from control cells after 72 hour of serum starvation, incubated 
with rhPGRN in the absence or in the presence of elastase. As shown in Fig. 2B right panel, PGRN seems 
to be remarkably stable in the neuronal medium. In contrast, extracellular PGRN was significantly 
degraded by exogenous elastase (Fig. 2B). Taken together, these results suggest that the pro-survival 
effect of added rhPGRN is most likely due to the full-length protein rather than to granulin peptides. 
Serum withdrawal induces apoptosis 
Cell death induced by serum deprivation showed characteristics of apoptosis. First of all, the examination 
of serum-deprived control and GRN KD cells after DAPI staining with a fluorescence microscopy 
revealed the abundance of chromatin condensation fragments (arrows) in the nuclei of GRN KD cells 
(Fig. 3A). On the other hand, fluorescent cell distribution using FLICA green fluorescent probe indicates 
higher activity of executive caspases 3 and 7 (Fig. 3B) in PGRN deficient cells when compared with 
control cells, as FLICA binds irreversibly to these enzymes when are activated [32], thus increasing the 
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fluorescence signal in apoptotic cells. Moreover, we observed that serum deprivation induced a higher 
release of cytochrome c to the cytosolic compartment in PGRN deficient cells than in control cells (Fig. 
4). These results suggest the activation of the intrinsic (mitochondrial activated) pathway. 
Role of C D K4/6/pRb pathway on cell survival 
We had previously shown that PGRN deficit altered the activity of CDK4/6–associated kinase and 
survival of peripheral cells from FTLD-TDP patients bearing a GRN null mutation [29]. On these 
grounds, we were interested in evaluating the role of the CDK4/6/pRb pathway in the survival/death of 
control and PGRN-depleted neuroblastoma cell lines under serum deprivation conditions. Western blot 
analysis revealed a significant higher content of CDK4 and CDK6 in control cells, compared with KD 
cells. Consequently, an elevated CDK activity,as determined by the higher phosphorylation status of the 
retinoblastoma protein (pRb), was also observed in control cells (Fig. 5A). To investigate if CDK4/6 
levels determine the ability of the GRN knockdown cells to survive in serum deprived medium, we 
inhibited CDK4/6 activity, either with an inhibitor of histone deacetylases (HDAC), such as sodium 
butyrate (SB), to blunt the CDK4 and CDK6 mRNA expression or with the small molecule PD332991 
(Pfizer) that specifically inhibits the CDK4/6-associated kinase activity. Incubation of control cells with 
SB reduced CDK4 and CDK6 protein levels (Fig. 5A upper panel). Both SB and PD332991 inhibited 
CDK4/6-associated kinase activity as indicated by the decrease in the phosphorylation status of pRb (Fig. 
5A, lower panel). In these conditions, control cells died as PGRN-depleted cells did (Fig. 5B).  
Signaling pathways involved in the serum deprivation-mediated stimulation of cell death 
Two signaling cascades have emerged as major players in the control of survival/death of many different 
cells: the mitogen-activated protein kinase (MAPK) and the phosphoinositide-3 kinase (PI3K) pathways 
[33-35]. Both pathways are more active in control than in GRN KD cells as indicated by the higher 
phosphorylation status of Akt and ERK1/2 (Fig. 6A). The potential participation of these signaling 
pathways in controlling cell survival was analyzed by using pharmacological inhibitors.  We tested the 
effects of PD98059, inhibitor of MEK1/2, the upstream activator of ERK1/2, and LY294002, inhibitor of 
PI3K. We confirmed the effect of these inhibitors on the phosphorylation status of their respective kinases 
(Fig. 6B). LY294002 inhibited the Akt phosphorylation without affecting ERK1/2 phosphorylation status 
whereas PD98059 decreased ERK1/2 phosphorylation but did not modify Akt phosphorylation (Fig. 6A). 
As shown in Fig. 6B, both LY294002 and PD98059 sensitized control cells to cell death induced by 
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serum deprivation. Under these experimental conditions, control cells underwent apoptosis as did GRN 
KD cells. These findings suggest that PGRN deficiency impaired the activation of these two survival 
pathways. Inhibition of PI3K/Akt by LY294002, as well as the inhibition of ERK1/2 phosphorylation by 
PD98059 decreased the content of CDK6 in control cells to levels found in GRN KD cells (Fig. 7). Both 
inhibitors were also effective in decreasing the phosphorylation of pRb protein (Fig. 7). Taken together, 
these results suggest that cell fate (survival or death) ultimately relies on the activity of CDK6/pRb, 
which appear to be controlled by the PI3K/Akt and ERK1/2 pathways. 
Exogenous P G RN normalizes the PI3K /A kt and E R K1/2 activity in GRN K D cells 
We evaluated next whether the addition of rhPGRN to the incubation medium was able to increase 
PI3K/Akt and ERK1/2 activities. As shown in Fig. 8, rhPGRN restored the phosphorylation status of both 
Akt (Fig. 8A, left panel) and ERK1/2 (Fig. 8A, right panel) in PGRN deficient cells. In addition, it is 
shown that rhPGRN normalized CDK4 and CDK6 levels and pRb phosphorylation in GRN KD cells, 
reaching similar to control cells (Fig. 8B).  
Effects of E G F and insulin on survival of GRN K D neuronal cells 
Since PGRN deficiency seems to result in decreased PI3K/Akt and ERK1/2 activities, we sought to 
evaluate if GRN KD cells could be rescued from death induced by serum deprivation in the presence of 
other physiologically relevant activators of these pathways such as EGF or insulin [36,37]. As expected, 
both EGF and insulin increased the levels of pAkt and pERK1/2 (Fig. 9 upper panel). Under these 
conditions, GRN KD cells were able to survive in the absence of serum (Fig. 9 lower panel).  
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DISC USSI O N 
Loss-of-function GRN mutations are casually associated with FTLD, however, how the PGRN deficit 
induces specific neuronal death remains to be determined. In this work we have addressed the question as 
to whether knocking down the GRN gene in human neuroblastoma cells SH-SY5Y, determines the cell 
fate, survival/death, in response to a cell stressor like serum withdrawal. In addition, we have investigated 
the influence of PGRN deficiency on the PI3K/Akt and ERK1/2 signaling pathways. Our results indicate 
that PGRN deficient cells are more vulnerable to serum deprivation. The GRN KD cells show features of 
apoptosis, as increased activation of executive caspases and cytochrome c released from the mitochondria 
compared with control cells.  
Addition of rhPGRN to the culture medium of GRN KD cells protects them from the serum withdrawal-
induced apoptosis, suggesting that PGRN acts primarily through an extracellular mechanism. 
Interestingly, the effect of exogenous PGRN is most likely due to the full-length protein, rather than to 
granulin peptides.  
In agreement with previous reports from this laboratory that revealed an important role for CDK4/6/pRb 
pathway in controlling survival of lymphoblasts from carriers of a loss-of-function GRN mutation [29], 
we observed in GRN KD neuroblastoma cells significant changes in the levels of CDK4 and CDK6 and 
the phosphorylation status of pRb protein. Increased signaling through CDK4/6/pRb pathway was 
associated with a survival advantage in both lymphoblasts and neuroblastoma cells. However, PGRN 
deficiency induced opposites changes in CDK4/6/pRb and cell resistance to serum deprivation in 
lymphoblasts and SH-SY5Y cells. Thus it seems that PGRN influences cell fate survival/death in cell 
type-specific manner. Exogenous rhPGRN was able to increase cell viability in GRN KD neuroblastoma 
cells to levels similar to control cells. In a similar way rhPGRN was able  to  restore  the  “normal”  cell 
response to serum stimulation or withdrawal [29,38], by blunting the enhanced proliferative activity of 
PGRN-deficient lymphoblasts, or sensitizing cells to apoptosis in the absence or serum. The resistance of 
FTLD lymphoblasts towards a proapototic stimuli such as serum withdrawal may be explained by the 
tumor-like features of these cell lines, which it is believed reflects, at the systemic level, the proposed 
relationship between cellular stress and unscheduled cell cycle entry observed in susceptible neurons in 
neurodegenerative disorders [39,40]. Thus the possibility should be considered that the reduced 
CDK4/6/pRb activity, induced by PGRN deficiency in neuroblastoma cell lines could represent an 
attempt to blunt cell cycle progression of vulnerable neurons under conditions of chronic stress. 
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The involvement of CDK4/6/pRb in the control of the response of SH-SY5Y cells to serum deprivation is 
further supported by the fact that survival of control cells is reduced in the presence of specific inhibitors 
of either CDK4 and CDK6 expression levels or the CDK4/6-associated kinase activity such as SB or 
PD332991 respectively. The effects of these two drugs on survival of SH-SY5Y cells are in consonance 
with the reported effect of PD332991 on myeloma, increasing the cell sensitivity to bortezomib-induced 
apoptosis [41] and with the observation that knockdown of CDK6 enhanced the susceptibility of glioma 
cells to chemotherapy [42]. The fact that these drugs did not affect survival of PGRN-deficient cells, 
suggest a threshold for CDK4/6-associated kinase activity as the survival signal. Our results are in 
consonance with previous reports indicating a role of the CDK/pRb pathway in maintaining the 
postmitotic state throughout the lifetime of neurons [43]. Moreover, an anti-apoptotic role for CDK/pRb 
has been suggested, since a correlation between pRb loss and induction of apoptosis appears to occur in 
as pRb-/- null mice [44]. Nonetheless, our results contrast with other works suggesting a role of increased 
CDK6 activity in neuronal cell death [45,46], and neuroprotection through the inhibition of specific 
CDKs has been demonstrated [47,48]. Thus, it seems that activation of CDK/pRb can have a pro- or anti-
apoptotic role in neuronal cells depending perhaps on the cell status or the nature of the cell stressor.  
Analysis of the molecular signaling changes during serum deprivation in GRN knockdown cells revealed 
significant differences in the level of phosphorylated Akt and ERK1/2 compared with control cells. GRN 
KD cells showed impaired activation of both pathways. Treatment of control cells with the PI3K/Akt 
inhibitor LY294002 or the ERK1/2 inhibitor PD98059 induced significant apoptosis to levels similar to 
GRN KD cells. Therefore, it seems that PGRN may protect against apoptosis induced by serum 
withdrawal by activating the PI3K/Akt and ERK1/2 survival pathways. Indeed, we could observe the 
activating effects of rhPGRN in PI3K/Akt and ERK1/2 in PGRN-deficient neuroblastoma cells. This 
observation is in consonance with in previous reports showing the involvement of PGRN in activating 
these signaling pathways in a number of cell types [49,50], and in the reported anti-apoptotic effect of 
PGRN in primary neurons [51,22,52]. Moreover, activation of the PI3K/Akt and ERK1/2 pathways  by 
EGF or insulin was sufficient to support survival of GRN KD cells in the absence of serum. 
Our data suggest that CDK4/6 is a target of both PI3K/Akt and ER1/2 signaling pathways since the 
effects of LY294002 or PD98059 inducing apoptosis in control cells are accompanied by a significant 
decrease in CDK4 and CDK6 levels. In a similar way, ablation of Akt was shown to downregulate CDK4 
and CDK6 expression [53,54]. Thus, it seems that PGRN-dependent PI3K/Akt and ERK1/2 activation 
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plays a critical role as mediator of cell survival by regulating the activity of the CDK4/6/pRb pathway. 
The proposed scenario is represented schematically in Fig. 10. The nature of the link between PGRN 
deficiency, PI3K/Akt and ERK1/2 signaling and CDK4/6/pRb activity remains to be resolved. Changes in 
signaling molecules and/or receptors can occur in PGRN deficiency, for example, alterations in 
circulating cytokines were detected in serum of FTLD patients carriers of a loss-of-function GRN 
mutation [55], and changes in Wnt signaling had been found in cells from FTLD patients [56,57]. This 
issue is currently under investigation in our laboratory. 
 
Together, our data indicate a neuroprotective role for PGRN and provide further support for the premise 
that chronic PGRN deficiency in FTLD results in reduced survival signaling and increased neuronal 
vulnerability to cellular stressors, leading to increased rates of neuronal cell death. Treatment with 
exogenous PGRN or alternatively with activators of the PI3K/Akt and ERK1/2 pathways may be useful 
for prevention and treatment of FTLD-TDP associated to PGRN haploinsufficency. 
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F I G UR E L E G E NDS: 
 
F ig. 1 
K nockdown of GRN in SH-SY5Yneuroblastoma cells reduced cell viability following serum 
deprivation 
Whole-cell extracts of SH-SY5Y clones expressing either the control vector or a target sequence of 
human GRN mRNA, were analyzed for the expression of GRN mRNA by quantitative RT-PCR (A), and 
protein levels by Western blotting using specific antibodies (B). β-actin levels were analyzed as loading 
controls. Values shown for the densitometric analyses are the mean ± standard error of the mean (SEM) 
for four experiments. **p<0.01 and ***p<0.001 significantly  different from control cells. (C) Survival of 
control (open symbols) and GRN KD cells (filled symbols) following serum deprivation. A total of 
60,000 cells per well were seeded in a 96-well plaque and incubated in the absence of serum for the time 
period indicated. Cell viability was determined by the MTT assay and expressed as percentage of the 
value at day 0. Data shown are the mean ± SEM for six determinations carried in triplicate. *p<0.05 and 
***p<0.001 significantly different from control. 
 
F ig. 2 
Exogenous progranulin restores the survival of GRN K D cells 
(A) A total of 600,000 control and GRN KD cells were seeded and incubated in serum-free DMEM 
medium during 72 hours in the absence or in the presence of 100 ng/ml of recombinant human 
progranulin (rhPGRN). Cell number was determined by counting the cells excluding trypan blue using a 
TC10™ Automated Cell Counter. Values shown are the mean ± SEM of seven experiments. ***p<0.001 
significantly different from control cells; †††p<0.001 significantly different from untreated GRN KD 
cells.  (B) rhPGRN (100 ng/ml) was incubated in the absence and presence of 0.1 U/ml of elastase for 3 
hours (left panel) and the levels of PGRN protein were determined by Western blot. PGRN levels were 
also determined in conditioned medium from rhPGRN-treated cells in the absence or in the presence of 
elastase (right panel). Representative immunoblots are shown.  
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F ig. 3 
Progranulin deficiency sensitizes cells to serum withdrawal-induced apoptosis 
(A) Representative photomicrograph of 4,6-diamidino-2-phenylindole (DAPI)-stained control and GRN 
KD SH-SY5Y cells after 72 hours of serum deprivation. Arrows show the presence of chromatin 
condensation/fragmentation indicating apoptosis. (B) Caspase activation in serum-deprived control and 
GRN KD cells. Cells were incubated as above and then labeled with the FLICA reagent following the 
manufacture’s  recommendation  to  detect  its  binding  to  active  caspases  3  and  7. A  representative  flow 
cytometric analysis of the frequency distribution of cells according to their green fluorescence is shown.  
 
F ig. 4 
Enhanced release of cytochrome c to the cytosol in serum-deprived GRN K D neuroblastoma SH-
SY5Y cells 
Control and GRN KD cells were serum deprived for 72 hours. Cell lysates were fractionated to isolate 
cytoplasmic and crude mitochondria. The presence of cytochrome c in cytosolic and mitochondrial 
fractions was assessed by Western blot analysis using the ApoTrack™ antibody cocktail, which 
demonstrates the purity of the fractions and loading. A representative blot is shown. Densitometric 
analyses are presented below. The data represent the mean ± SEM of the mitochondrial and cytosolic 
cytochrome c for four independent experiments. *p<0.05 and **p<0.01  significantly different from 
control cells. 
 
F ig. 5 
E ffects of sodium butyrate and PD332991 on C D K4/6 protein levels, phosphorylation status of pRb 
and cell survival 
(A) Control and GRN KD cells were incubated in serum-free medium for 72 hours in the absence or in 
the presence of 10 µM sodium butyrate (SB) or 1 µM PD332991. Representative immunoblots are 
shown. Densitometric analyses are presented in the right panel. Values shown are the mean ± SEM for 
ten experiments. ***p<0.001 significantly different from control cells and ††p<0.01; †††p<0.001 
significantly different from untreated cells.  (B) Cell survival was determined by the MTT assay and 
expressed as percentage of survival in untreated cells. Values shown are the mean ± SEM for four 
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independent experiments. **p<0.01 significantly different from control cells. †p<0.05 significantly 
different from untreated cells. 
 
F ig. 6 
E ffects of PI3K /A kt and M E K1/2 kinase inhibitors on serum withdrawal-induced loss of cell 
viability 
(A) Control and GRN KD cells were incubated in serum-free medium for 24 hours in the absence or in 
the presence of 10 µM LY294002 or 20 µM PD98059. The relative levels of activation of ERK1/2 and 
Akt were assessed by Western blot analysis using phospho-specific antibodies. Representative 
immunoblots are shown. Densitometric analyses are presented in the right panel. Values shown are the 
mean ± SEM of five experiments. *p<0.05 and ***p<0.001 significantly  different from control cells and 
†††p<0.001 significantly different from untreated cells. (B) Control and GRN KD cells were incubated in 
the absence and in the presence of different kinases inhibitors as above. Cell viability was assessed by 
measuring the MTT reduction and expressed as percentage of cell survival in untreated control cells. 
Values shown are the mean ± SEM for seven experiments. ***p<0.001 significantly different from 
control cells and †††p<0.001 significantly different from untreated cells. 
 
F ig. 7 
E ffects of PI3K /A kt and M E K1/2 kinase inhibitors on C D K4/6 levels and phosphorylation status of 
pRb in control and GRN K D neuroblastoma SH-SY5Y 
Control and GRN KD cells were incubated in serum-free medium for 72 hours in the absence or in the 
presence of 10 µM LY294002 or 20 µM PD98059. The levels of CDK4, CDK6 and pRb were assessed 
by Western blot analysis using specific antibodies. Representative immunoblots are shown. Densitometric 
analyses are presented in the right panel. Values shown are the mean ± SEM of five to ten experiments. 
*p<0.05, ***p<0.001 significantly different from control cells. †p<0.05, ††p<0.01, †††p<0.001 
significantly different from untreated  control cells. 
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F ig. 8 
E ffects of rhPG RN on PI3K /A kt, E R K1/2, and C D K4/6/pRb pathways 
(A) Control and GRN KD cells were incubated in serum-free medium for 24 hours in the absence or in 
the presence of 100 ng/ml of recombinant human progranulin (rhPGRN). Representative immunoblots for 
Akt and ERK1/2 are shown in the left, while densitometric analyses are presented in the right. Values 
shown are the mean ± SEM of five experiments. (B) Representative immunoblots showing the effects of 
rhPGRN in CDK4 and CDK6 levels and phosphorylation status of the pRb protein. Densitometric 
analyses of CDK4 and CDK6 levels are presented in the right panel. Values shown are the mean ± SEM 
of five experiments **p<0.01, ***p<0.001 significantly different from control cells. †p<0.05 
significantly different from untreated  GRN KD cells. 
F ig. 9 
E ffects of E G F and insulin on survival of GRN K D neuroblastoma SH-SY5Y cells 
Control and GRN KD cells were incubated in serum-free medium for 72 hours in the absence or in the 
presence of of 100 ng/ml of EGF or 100nM of insulin.  Cell extracts for immunoblotting were prepared 
24 hours after growth factor addition. Representative immunoblots showing the effects of EGF and 
insulin on pAkt and pERK1/2 levels are presented in the upper panel. Lower panel: Cell viability was 
assessed 72 hours after serum deprivation and addition of EGF or insulin, by measuring the MTT 
reduction. Values shown are the mean ± SEM for three experiments carried out in triplicate. * p<0.05 
significantly different from control cells and † p<0.05, †† p<0.01 significantly different from untreated 
cells. 
 
F ig. 10 
Influence of PG RN deficiency on the activation of survival pathways under conditions of serum 
deprivation 
Compared with control cells, GRN KD neuroblastoma SH-SY5Y cells showed reduced activation of both 
PI3K/Akt and ERK1/2 pathways in response to serum deprivation, which then results in decreased 
activity of CDK6/pRb and stimulation of apoptosis. Treatment of GRN KD cells with rhPGRN 
normalized the cell survival response. In contrast treatment of control cells with specific inhibitors of 
CDK4/6, PI3K/Akt and ERK1/2 pathways sensitized control cells to serum withdrawal-induced 
apoptosis. 
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Table 1 
 
Summary of antibodies used for Western blotting 
Antibody name Company Dilution 
Anti-granulin (EPR3781) Abcam (ab108608) 1:500 
Cytochrome c Apoptosis WB Antibody Cocktail Abcam (ab110415) 1:250 
β-actin (ACTBD11B7) 
CDK4 (C-22) 
Santa Cruz (sc-81178) 
Santa Cruz (sc-260) 
1:500 
1:500 
CDK6 (C-21) Santa Cruz (sc-177) 1:1000 
Rb (C-15) Santa Cruz (sc-50) 1:500 
α-tubulin (B-5-1-2) Santa Cruz (sc-23948) 1:1000 
Phospho-Akt (Ser473) (D9E) XP Cell Signaling (#4060) 1:1000 
Akt1 (C-20) Santa Cruz (sc-1618) 1:1000 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) XP Cell Signaling (#4370) 1:2000 
p44/42 MAP Kinase Cell Signaling (#9102) 1:2000 
Key: ERK, extracellular-regulated kinase; MAPK, mitogen-activated protein kinase. 
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